A physician is urging the U.S. Food and Drug Administration to apply closer scrutiny to medications that raise blood pressure, arguing that even modest increases may carry meaningful cardiovascular risks that are not always fully reflected in current drug approval or labeling practices.
In a recent editorial published in the Journal of Cardiovascular Pharmacology and Therapeutics, Robert P. Blankfield raised concerns about how blood-pressure-related side effects are evaluated during medication review…. Continue Reading ⬇️
1 2